Livitol-70

PreclinicalSmall molecule

CComposite Interceptive Med Science

Livitol-70 is one of 2 small molecule programs targeting Alcoholic Liver Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcoholic Liver DiseaseActive, not recruiting

Alcoholic Liver DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Alcoholic Liver Disease

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Approved

—2

Livitol-70

CComposite Interceptive Med Science

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

N/ANot yet recruiting

Alcoholic Liver Disease

NCT03503708

Clinical

Trials by Indication[1]

Alcoholic Liver Disease1 trial

Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease

Not yet recruiting·CComposite Interceptive Med Science·N/A·NCT03503708·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Livitol-70. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Livitol-70 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Livitol-70. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Composite Interceptive Med Science company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CComposite Interceptive Med Science

Livitol-70

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Alcoholic Liver Disease1 trial

References

Drug Info

Quick Facts

Related News